Drug Trial Radar · NCT05508789
A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)
Last checked: Nov 20, 2026Latest source record: Sep 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
1,500
Planned (sponsor's estimate)
Start
Oct 10, 2022
Primary completion
May 2028
Study completion Jul 2028
Sponsor
- Lead sponsor
- Eli Lilly and CompanyEli Lilly (LLY)
- Sponsor type
- Industry
- First posted
- Aug 19, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 60 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The reason for this study is to assess the safety and efficacy of donanemab in participants with early Alzheimer's disease. The study duration including screening and follow-up is up to 93 weeks.
Conditions
- Alzheimer Disease
- Dementia
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Tauopathies
- Neurodegenerative Diseases
- Neurocognitive Disorders
- Mental Disorders
Interventions
DonanemabDrug
Administered IV
PlaceboDrug
Administered IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from Baseline on the Integrated Alzheimer's Disease Rating Scale (iADRS)Time frame: Baseline, Week 76
Locations
141 sites in 8 countries. Site status is shown where the registry gives one.
Hospital Italiano de Buenos Aires
ABB, Argentina
Clinica Privada Banfield
Banfield, Argentina
Fundación para el Estudio y Tratamiento de Enfermedades Mentales (FETEM)
Buenos Aires, Argentina
Stat Research S.A.
Buenos Aires, Argentina
Centro de Investigaciones Metabólicas (CINME)
Buenos Aires, Argentina
CIPREC
Buenos Aires, Argentina
Mautalen Salud e Investigación
Buenos Aires, Argentina
Centro Medico Dra. Laura Maffei- Investigacion Clinica Aplicada
Buenos Aires, Argentina
Centro Médico Arsema
Buenos Aires, Argentina
Instituto Geriatrico Nuestra Señora de Las Nieves
Buenos Aires, Argentina
Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia (FLENI)
Buenos Aires, Argentina
Centro de Educación Médica e Investigaciones clínicas "Dr. Norberto Quirno" (CEMIC)
Buenos Aires, Argentina
IDIM - Instituto de Investigaciones Metabólicas
Ciudad de Buenos Aires, Argentina
INSA Instituto de Neurociencia San Agustin
La Plata, Argentina
Instituto De Investigaciones Clinicas Quilmes
Quilmes, Argentina
INECO Neurociencias Oroño
Rosario, Argentina
Emeritus Research
Botany, Australia
Box Hill Hospital
Box Hill, Australia
The Prince Charles Hospital
Brisbane, Australia
NeuroCentrix
Carlton, Australia
Central Coast Neurosciences Research
Erina, Australia
Austin Health
Ivanhoe, Australia
Southern Neurology
Kogarah, Australia
HammondCare
Malvern, Australia
The Alfred Hospital
Melbourne, Australia
Alzheimer's Research Australia
Nedlands, Australia
The Royal Melbourne Hospital
Parkville, Australia
St Vincent's Hospital
Sydney, Australia
KARA Institute for Neurological Diseases
Sydney, Australia
Central Coast Neurosciences Research (Tumbi Umbi)
Tumbi Vmbi, Australia
Neurodegenerative Disorders Research
West Perth, Australia
The Queen Elizabeth Hospital
Woodville, Australia
Beijing Hospital
Beijing, China
Beijing ChaoYang Hospital
Beijing, China
Beijing Friendship Hospital Affiliate of Capital University
Beijing, China
Xuanwu Hospital Capital Medical University
Beijing, China
Beijing Tiantan Hospital Affiliated to Capital Medical University
Beijing, China
Beijing Anding Hospital - Affiliated Capital University of Medical Science
Beijing, China
Beijing Peking Union Medical College Hospital
Beijing, China
Chinese PLA General Hospital
Beijing, China
Showing 40 of 141 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.